Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 4Pancreatic Intraductal Neoplasms 2

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 228Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × tocotrienol, delta × Gastrointestinal × Clear all
NCT06519097 2025-11-13

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
4 enrolled
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

NCT01450046 2016-07-07

Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01446952 2016-04-11

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00985777 2016-03-01

Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
26 enrolled
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡